The NHS doesn’t offer bowel screening until we’re 50. Yet with cancer rates rising, it may be worth forking out for a private ...

Metastatic colorectal cancer with microsatellite instability-high or mismatch repair-deficient status represents a distinct ...

Patients with metastatic colorectal cancer (mCRC) harboring BRAF V600E mutations benefitted from first-line treatment with ...

Patients with metastatic colorectal cancer (mCRC) harboring BRAF V600E mutations benefited from first-line treatment with the targeted therapies encorafenib and cetuximab plus a mFOLFOX6 chemotherapy ...

Neoadjuvant Keytruda for patients with deficient DNA mismatch repair colon cancer resulted in a pathological complete ...

Although ctDNA positivity generally meant worse disease-free survival in stage 3 resected colon cancer, patients with ctDNA ...

A data analysis from a randomized clinical trial for stage 3 colon cancer patients by investigators at Dana-Farber Brigham ...

The Alliance for Clinical Trials in Oncology today announced the results of a data analysis from a randomized phase III clinical trial involving patients with stage III colon cancer, which found that ...

PALO ALTO, Calif. - Guardant Health , Inc. (NASDAQ: NASDAQ:GH), a precision oncology company with a market capitalization of ...

Safety: Aspirin was well-tolerated, with no major safety concerns reported. The ASCOLT trial showed that aspirin did not ...

Machine learning and artificial intelligence (AI) techniques and analysis of large datasets have helped University of ...